A CRISPR toolbox to study virus-host interactions

Nature Reviews Microbiology

Volumn 15, Issue 6, 2017, Pages 351-364

  Puschnik, Andreas S ^a   Majzoub, Karim ^a   Ooi, Yaw Shin ^a   Carette, Jan E ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM; BIOINFORMATICS; CELL LINE; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEAT; CRISPR CAS SYSTEM; DNA VIRUS; ESSENTIAL GENE; GAIN OF FUNCTION MUTATION; GENE EDITING; GENETIC SCREENING; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNE SYSTEM; IN VITRO STUDY; IN VIVO STUDY; LOSS OF FUNCTION MUTATION; MUTAGENESIS; NEXT GENERATION SEQUENCING; NONHUMAN; NOROVIRUS; PARASITE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHENOTYPE; PRIORITY JOURNAL; REPRODUCIBILITY; REVIEW; SIGNAL TRANSDUCTION; VALIDATION STUDY; VIRUS CELL INTERACTION; VIRUS GENE; VIRUS GENOME; VIRUS INFECTION; DENGUE VIRUS; GENE INACTIVATION; GENETICS; HEPACIVIRUS; HIGH THROUGHPUT SCREENING; PROCEDURES; RNA INTERFERENCE; VIRUS REPLICATION; WEST NILE VIRUS; ZIKA VIRUS;

CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEATS; CRISPR-CAS SYSTEMS; DENGUE VIRUS; GENE KNOCKOUT TECHNIQUES; HEPACIVIRUS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; RNA INTERFERENCE; VIRUS REPLICATION; WEST NILE VIRUS; ZIKA VIRUS;

EID: 85017621411     PISSN: 17401526     EISSN: 17401534     Source Type: Journal    
DOI: 10.1038/nrmicro.2017.29     Document Type: Review

References (167)

1. Brenner, S. The genetics of Caenorhabditis elegans. Genetics 77, 71-94 (1974).
2. Hartwell, L. H., Culotti, J. & Reid, B. Genetic control of the cell-division cycle in yeast. I. Detection of mutants. Proc. Natl Acad. Sci. USA 66, 352-359 (1970).
3. Rutschmann, S. et al. Role of Drosophila IKK? in a toll-independent antibacterial immune response. Nat. Immunol. 1, 342-347 (2000).
4. Nusslein-Volhard, C. & Wieschaus, E. Mutations affecting segment number and polarity in Drosophila. Nature 287, 795-801 (1980).
5. Berns, K. et al. A large-scale RNAi screen in human cells identifies new components of the p53 pathway. Nature 428, 431-437 (2004).
6. Paddison, P. J. et al. A resource for large-scale RNAinterference-based screens in mammals. Nature 428, 427-431 (2004).
7. Carette, J. E. et al. Haploid genetic screens in human cells identify host factors used by pathogens. Science 326, 1231-1235 (2009).
8. Cong, L. et al. Multiplex genome engineering using CRISPR/Cas systems. Science 339, 819-823 (2013).
9. Mali, P. et al. RNA-guided human genome engineering via Cas9. Science 339, 823-826 (2013).
10. Jinek, M. et al. RNA-programmed genome editing in human cells. eLife 2, e00471 (2013).
11. Evers, B. et al. CRISPR knockout screening outperforms shRNA and CRISPRi in identifying essential genes. Nat. Biotechnol. 34, 631-633 (2016).
12. DeJesus, R. et al. Functional CRISPR screening identifies the ufmylation pathway as a regulator of SQSTM1/p62. eLife 5, e17290 (2016).
13. Hart, T. et al. High-resolution CRISPR screens reveal fitness genes and genotype-specific cancer liabilities. Cell 163, 1515-1526 (2015).
14. Shalem, O. et al. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science 343, 84-87 (2014).
15. Wang, T., Wei, J. J., Sabatini, D. M. & Lander, E. S. Genetic screens in human cells using the CRISPR-Cas9 system. Science 343, 80-84 (2014).
16. Shalem, O., Sanjana, N. E. & Zhang, F. Highthroughput functional genomics using CRISPR-Cas9. Nat. Rev. Genet. 16, 299-311 (2015).
17. Zhou, Y. et al. High-throughput screening of a CRISPR/ Cas9 library for functional genomics in human cells. Nature 509, 487-491 (2014).
18. Evans, M. J. et al. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature 446, 801-805 (2007).
19. Ploss, A. et al. Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature 457, 882-886 (2009).
20. Saeed, M. et al. SEC14L2 enables pan-genotype HCV replication in cell culture. Nature 524, 471-475 (2015).
21. Schoggins, J. W. et al. Pan-viral specificity of IFNinduced genes reveals new roles for cGAS in innate immunity. Nature 505, 691-695 (2014).
22. Schoggins, J. W. et al. A diverse range of gene products are effectors of the type I interferon antiviral response. Nature 472, 481-485 (2011).
23. ORFeome Collaboration. The ORFeome Collaboration: a genome-scale human ORF-clone resource. Nat. Methods 13, 191-192 (2016).
24. Ramage, H. & Cherry, S. Virus-host interactions: from unbiased genetic screens to function. Annu. Rev. Virol. 2, 497-524 (2015).
25. Carette, J. E. et al. Ebola virus entry requires the cholesterol transporter Niemann-Pick C1. Nature 477, 340-343 (2011).
26. Jae, L. T. et al. Lassa virus entry requires a trigger-induced receptor switch. Science 344, 1506-1510 (2014).
27. Miller, E. H. et al. Ebola virus entry requires the hostprogrammed recognition of an intracellular receptor. EMBO J. 31, 1947-1960 (2012).
28. Cote, M. et al. Small molecule inhibitors reveal Niemann-Pick C1 is essential for Ebola virus infection. Nature 477, 344-348 (2011).
29. Bornholdt, Z. A. et al. Host-primed Ebola virus GP exposes a hydrophobic NPC1 receptor-binding pocket, revealing a target for broadly neutralizing antibodies. mBio 7, e02154-15 (2016).
30. Gong, X. et al. Structural insights into the Niemann-Pick C1 (NPC1)-mediated cholesterol transfer and Ebola infection. Cell 165, 1467-1478 (2016).
31. Wang, H. et al. Ebola viral glycoprotein bound to its endosomal receptor Niemann-Pick C1. Cell 164, 258-268 (2016).
32. Diehl, W. E. et al. Ebola virus glycoprotein with increased infectivity dominated the 2013-2016 epidemic. Cell 167, 1088-1098.e6 (2016).
33. Urbanowicz, R. A. et al. Human adaptation of Ebola virus during the West African outbreak. Cell 167, 1079-1087.e5 (2016).
34. Staring, J. et al. PLA2G16 represents a switch between entry and clearance of Picornaviridae. Nature 541, 412-416 (2017).
35. Pillay, S. et al. An essential receptor for adeno-associated virus infection. Nature 530, 108-112 (2016).
36. Schmidt, T., Schmid-Burgk, J. L. & Hornung, V. Synthesis of an arrayed sgRNA library targeting the human genome. Sci. Rep. 5, 14987 (2015).
37. Essletzbichler, P. et al. Megabase-scale deletion using CRISPR/Cas9 to generate a fully haploid human cell line. Genome Res. 24, 2059-2065 (2014).
38. Sagi, I. et al. Derivation and differentiation of haploid human embryonic stem cells. Nature 532, 107-111 (2016).
39. Elling, U. et al. Forward and reverse genetics through derivation of haploid mouse embryonic stem cells. Cell Stem Cell 9, 563-574 (2011).
40. Leeb, M. & Wutz, A. Derivation of haploid embryonic stem cells from mouse embryos. Nature 479, 131-134 (2011).
41. Wutz, A. Haploid mouse embryonic stem cells: rapid genetic screening and germline transmission. Annu. Rev. Cell Dev. Biol. 30, 705-722 (2014).
42. Pillay, S. & Carette, J. E. Hunting viral receptors using haploid cells. Annu. Rev. Virol. 2, 219-239 (2015).
43. Sanjana, N. E., Shalem, O. & Zhang, F. Improved vectors and genome-wide libraries for CRISPR screening. Nat. Methods 11, 783-784 (2014).
44. Doench, J. G. et al. Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9. Nat. Biotechnol. 34, 184-191 (2016).
45. Wang, T. et al. Identification and characterization of essential genes in the human genome. Science 350, 1096-1101 (2015).
46. Liu, S. J. et al. CRISPRi-based genome-scale identification of functional long noncoding RNA loci in human cells. Science 355, aah7111 (2016).
47. Joung, J. et al. Genome-scale CRISPR-Cas9 knockout and transcriptional activation screening. Nat. Protoc. 12, 828-863 (2017).
48. Burns, J. C., Friedmann, T., Driever, W., Burrascano, M. & Yee, J. K. Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells. Proc. Natl Acad. Sci. USA 90, 8033-8037 (1993).
49. Wool-Lewis, R. J. & Bates, P. Characterization of Ebola virus entry by using pseudotyped viruses: identification of receptor-deficient cell lines. J. Virol. 72, 3155-3160 (1998).
50. Xiong, C. et al. Sindbis virus: an efficient, broad host range vector for gene expression in animal cells. Science 243, 1188-1191 (1989).
51. Lohmann, V. et al. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285, 110-113 (1999).
52. Trono, D., Pelletier, J., Sonenberg, N. & Baltimore, D. Translation in mammalian cells of a gene linked to the poliovirus 5? noncoding region. Science 241, 445-448 (1988).
53. Simoes, E. A. & Sarnow, P. An RNA hairpin at the extreme 5? end of the poliovirus RNA genome modulates viral translation in human cells. J. Virol. 65, 913-921 (1991).
54. Luo, B. et al. Highly parallel identification of essential genes in cancer cells. Proc. Natl Acad. Sci. USA 105, 20380-20385 (2008).
55. Konig, R. et al. A probability-based approach for the analysis of large-scale RNAi screens. Nat. Methods 4, 847-849 (2007).
56. Li, W. et al. MAGeCK enables robust identification of essential genes from genome-scale CRISPR/Cas9 knockout screens. Genome Biol. 15, 554 (2014).
57. Fu, Y. et al. High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells. Nat. Biotechnol. 31, 822-826 (2013).
58. Hsu, P. D. et al. DNA targeting specificity of RNAguided Cas9 nucleases. Nat. Biotechnol. 31, 827-832 (2013).
59. Pattanayak, V. et al. High-throughput profiling of offtarget DNA cleavage reveals RNA-programmed Cas9 nuclease specificity. Nat. Biotechnol. 31, 839-843 (2013).
60. Blomen, V. A. et al. Gene essentiality and synthetic lethality in haploid human cells. Science 350, 1092-1096 (2015).
61. Marceau, C. D. et al. Genetic dissection of Flaviviridae host factors through genome-scale CRISPR screens. Nature 535, 159-163 (2016).
62. Wu, X., Li, Y., Crise, B. & Burgess, S. M. Transcription start regions in the human genome are favored targets for MLV integration. Science 300, 1749-1751 (2003).
63. Carette, J. E. et al. Global gene disruption in human cells to assign genes to phenotypes by deep sequencing. Nat. Biotechnol. 29, 542-546 (2011).
64. Timms, R. T. et al. Genetic dissection of mammalian ERAD through comparative haploid and CRISPR forward genetic screens. Nat. Commun. 7, 11786 (2016).
65. Bekerman, E. & Einav, S. Combating emerging viral threats. Science 348, 282-283 (2015).
66. Bhatt, S. et al. The global distribution and burden of dengue. Nature 496, 504-507 (2013).
67. Lessler, J. et al. Assessing the global threat from Zika virus. Science 353, aaf8160 (2016).
68. Cao-Lormeau, V. M. et al. Guillain-Barre syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study. Lancet 387, 1531-1539 (2016).
69. Ma, H. et al. A CRISPR-based screen identifies genes essential for West-Nile-virus-induced cell death. Cell Rep. 12, 673-683 (2015).
70. Zhang, R. et al. A CRISPR screen defines a signal peptide processing pathway required by flaviviruses. Nature 535, 164-168 (2016).
71. Savidis, G. et al. Identification of Zika virus and Dengue virus dependency factors using functional genomics. Cell Rep. 16, 232-246 (2016).
72. Cherepanova, N. A. & Gilmore, R. Mammalian cells lacking either the cotranslational or posttranslocational oligosaccharyltransferase complex display substrate-dependent defects in asparagine linked glycosylation. Sci. Rep. 6, 20946 (2016).
73. Fons, R. D., Bogert, B. A. & Hegde, R. S. Substratespecific function of the translocon-associated protein complex during translocation across the ER membrane. J. Cell Biol. 160, 529-539 (2003).
74. Olzmann, J. A., Kopito, R. R. & Christianson, J. C. The mammalian endoplasmic reticulum-associated degradation system. Cold Spring Harb. Perspect. Biol. 5, a013185 (2013).
75. Christianson, J. C. et al. Defining human ERAD networks through an integrative mapping strategy. Nat. Cell Biol. 14, 93-105 (2011).
76. Wideman, J. G. The ubiquitous and ancient ER membrane protein complex (EMC): tether or not? F1000Res. 4, 624 (2015).
77. Cruz-Oliveira, C. et al. Receptors and routes of dengue virus entry into the host cells. FEMS Microbiol. Rev. 39, 155-170 (2015).
78. Lavanchy, D. Evolving epidemiology of hepatitis C virus. Clin. Microbiol. Infect. 17, 107-115 (2011).
79. Brennan, C. M. & Steitz, J. A. HuR and mRNA stability. Cell. Mol. Life Sci. 58, 266-277 (2001).
80. Madan, V., Paul, D., Lohmann, V. & Bartenschlager, R. Inhibition of HCV replication by cyclophilin antagonists is linked to replication fitness and occurs by inhibition of membranous web formation. Gastroenterology 146, 1361-1372.e9 (2014).
81. Nag, A., Robotham, J. M. & Tang, H. Suppression of viral RNA binding and the assembly of infectious hepatitis C virus particles in vitro by cyclophilin inhibitors. J. Virol. 86, 12616-12624 (2012).
82. Luban, J., Bossolt, K. L., Franke, E. K., Kalpana, G. V. & Goff, S. P. Human immunodeficiency virus type 1 Gag protein binds to cyclophilins A and B. Cell 73, 1067-1078 (1993).
83. Lin, K. & Gallay, P. Curing a viral infection by targeting the host: the example of cyclophilin inhibitors. Antiviral Res. 99, 68-77 (2013).
84. Tan, M. & Jiang, X. Norovirus and its histo-blood group antigen receptors: an answer to a historical puzzle. Trends Microbiol. 13, 285-293 (2005).
85. Orchard, R. C. et al. Discovery of a proteinaceous cellular receptor for a norovirus. Science 353, 933-936 (2016).
86. Haga, K. et al. Functional receptor molecules CD300lf and CD300ld within the CD300 family enable murine noroviruses to infect cells. Proc. Natl Acad. Sci. USA 113, E6248-E6255 (2016).
87. Jones, M. K. et al. Enteric bacteria promote human and mouse norovirus infection of B cells. Science 346, 755-759 (2014).
88. Park, R. J. et al. A genome-wide CRISPR screen identifies a restricted set of HIV host dependency factors. Nat. Genet. 49, 193-203 (2017).
89. Parnas, O. et al. A genome-wide CRISPR screen in primary immune cells to dissect regulatory networks. Cell 162, 675-686 (2015).
90. Shi, J. et al. Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death. Nature 526, 660-665 (2015).
91. Popov, L. M. et al. The adherens junctions control susceptibility to Staphylococcus aureus ?-toxin. Proc. Natl Acad. Sci. USA 112, 14337-14342 (2015).
92. Virreira Winter, S., Zychlinsky, A. & Bardoel, B. W. Genome-wide CRISPR screen reveals novel host factors required for Staphylococcus aureus ?-hemolysinmediated toxicity. Sci. Rep. 6, 24242 (2016).
93. Blondel, C. J. et al. CRISPR/Cas9 screens reveal requirements for host cell sulfation and fucosylation in bacterial type III secretion system-mediated cytotoxicity. Cell Host Microbe 20, 226-237 (2016).
94. Sidik, S. M. et al. A genome-wide CRISPR screen in toxoplasma identifies essential apicomplexan genes. Cell 166, 1423-1435.e12 (2016).
95. Peters, J. M. et al. A comprehensive, CRISPR-based functional analysis of essential genes in bacteria. Cell 165, 1493-1506 (2016).
96. Hou, P. et al. Genome editing of CXCR4 by CRISPR/ cas9 confers cells resistant to HIV-1 infection. Sci. Rep. 5, 15577 (2015).
97. Li, C. et al. Inhibition of HIV-1 infection of primary CD4+ T-cells by gene editing of CCR5 using adenovirus-delivered CRISPR/Cas9. J. Gen. Virol. 96, 2381-2393 (2015).
98. Wells, M. F. et al. Genetic ablation of AXL does not protect human neural progenitor cells and cerebral organoids from Zika virus infection. Cell Stem Cell 19, 703-708 (2016).
99. Tschaharganeh, D. F., Lowe, S. W., Garippa, R. J. & Livshits, G. Using CRISPR/Cas to study gene function and model disease in vivo. FEBS J. 283, 3194-3203 (2016).
100. Friedland, A. E. et al. Heritable genome editing in C. elegans via a CRISPR-Cas9 system. Nat. Methods 10, 741-743 (2013).
101. Dickinson, D. J., Ward, J. D., Reiner, D. J. & Goldstein, B. Engineering the Caenorhabditis elegans genome using Cas9-triggered homologous recombination. Nat. Methods 10, 1028-1034 (2013).
102. Bassett, A. R., Tibbit, C., Ponting, C. P. & Liu, J. L. Highly efficient targeted mutagenesis of Drosophila with the CRISPR/Cas9 system. Cell Rep. 4, 220-228 (2013).
103. Gratz, S. J. et al. Genome engineering of Drosophila with the CRISPR RNA-guided Cas9 nuclease. Genetics 194, 1029-1035 (2013).
104. Bean, A. G. et al. Studying immunity to zoonotic diseases in the natural host-keeping it real. Nat. Rev. Immunol. 13, 851-861 (2013).
105. Li, D. et al. Heritable gene targeting in the mouse and rat using a CRISPR-Cas system. Nat. Biotechnol. 31, 681-683 (2013).
106. Kistler, K. E., Vosshall, L. B. & Matthews, B. J. Genome engineering with CRISPR-Cas9 in the mosquito Aedes aegypti. Cell Rep. 11, 51-60 (2015).
107. Lei, S. et al. Increased and prolonged human norovirus infection in RAG2/IL2RG deficient gnotobiotic pigs with severe combined immunodeficiency. Sci. Rep. 6, 25222 (2016).
108. Hai, T., Teng, F., Guo, R., Li, W. & Zhou, Q. One-step generation of knockout pigs by zygote injection of CRISPR/Cas system. Cell Res. 24, 372-375 (2014).
109. Niu, Y. et al. Generation of gene-modified cynomolgus monkey via Cas9/RNA-mediated gene targeting in one-cell embryos. Cell 156, 836-843 (2014).
110. Kou, Z. et al. CRISPR/Cas9-mediated genome engineering of the ferret. Cell Res. 25, 1372-1375 (2015).
111. Oishi, I., Yoshii, K., Miyahara, D., Kagami, H. & Tagami, T. Targeted mutagenesis in chicken using CRISPR/Cas9 system. Sci. Rep. 6, 23980 (2016).
112. Belser, J. A., Eckert, A. M., Tumpey, T. M. & Maines, T. R. Complexities in ferret influenza virus pathogenesis and transmission models. Microbiol. Mol. Biol. Rev. 80, 733-744 (2016).
113. Yuan, M. et al. Efficiently editing the vaccinia virus genome by using the CRISPR-Cas9 system. J. Virol. 89, 5176-5179 (2015).
114. Bi, Y. et al. High-efficiency targeted editing of large viral genomes by RNA-guided nucleases. PLoS Pathog. 10, e1004090 (2014).
115. Yuen, K. S. et al. CRISPR/Cas9-mediated genome editing of Epstein-Barr virus in human cells. J. Gen. Virol. 96, 626-636 (2015).
116. Harris, A. F. et al. Field performance of engineered male mosquitoes. Nat. Biotechnol. 29, 1034-1037 (2011).
117. Burt, A. Heritable strategies for controlling insect vectors of disease. Phil. Trans. R. Soc. B 369, 20130432 (2014).
118. Carvalho, D. O. et al. Suppression of a field population of Aedes aegypti in Brazil by sustained release of transgenic male mosquitoes. PLoS Negl Trop. Dis. 9, e0003864 (2015).
119. Adelman, Z. N. & Tu, Z. Control of mosquito-borne infectious diseases: sex and gene drive. Trends Parasitol. 32, 219-229 (2016).
120. Hammond, A. et al. A CRISPR-Cas9 gene drive system targeting female reproduction in the malaria mosquito vector Anopheles gambiae. Nat. Biotechnol. 34, 78-83 (2016).
121. Hall, A. B. et al. A male-determining factor in the mosquito Aedes aegypti. Science 348, 1268-1270 (2015).
122. Price, A. A., Sampson, T. R., Ratner, H. K., Grakoui, A. & Weiss, D. S. Cas9-mediated targeting of viral RNA in eukaryotic cells. Proc. Natl Acad. Sci. USA 112, 6164-6169 (2015).
123. van Diemen, F. R. et al. CRISPR/Cas9-mediated genome editing of herpesviruses limits productive and latent infections. PLoS Pathog. 12, e1005701 (2016).
124. Dong, C. et al. Targeting hepatitis B virus cccDNA by CRISPR/Cas9 nuclease efficiently inhibits viral replication. Antiviral Res. 118, 110-117 (2015).
125. Kaminski, R. et al. Excision of HIV-1 DNA by gene editing: a proof-of-concept in vivo study. Gene Ther. 23, 690-695 (2016).
126. Zhen, S. et al. Harnessing the clustered regularly interspaced short palindromic repeat (CRISPR)/ CRISPR-associated Cas9 system to disrupt the hepatitis B virus. Gene Ther. 22, 404-412 (2015).
127. Liu, X., Hao, R., Chen, S., Guo, D. & Chen, Y. Inhibition of hepatitis B virus by the CRISPR/Cas9 system via targeting the conserved regions of the viral genome. J. Gen. Virol. 96, 2252-2261 (2015).
128. Kennedy, E. M. et al. Suppression of hepatitis B virus DNA accumulation in chronically infected cells using a bacterial CRISPR/Cas RNA-guided DNA endonuclease. Virology 476, 196-205 (2015).
129. Ramanan, V. et al. CRISPR/Cas9 cleavage of viral DNA efficiently suppresses hepatitis B virus. Sci. Rep. 5, 10833 (2015).
130. Deans, R. M. et al. Parallel shRNA and CRISPR-Cas9 screens enable antiviral drug target identification. Nat. Chem. Biol. 12, 361-366 (2016).
131. Harvey, R. et al. GSK983: a novel compound with broad-spectrum antiviral activity. Antiviral Res. 82, 1-11 (2009).
132. Barrangou, R. Diversity of CRISPR-Cas immune systems and molecular machines. Genome Biol. 16, 247 (2015).
133. Ran, F. A. et al. In vivo genome editing using Staphylococcus aureus Cas9. Nature 520, 186-191 (2015).
134. Abudayyeh, O. O. et al. C2c2 is a single-component programmable RNA-guided RNA-targeting CRISPR effector. Science 353, aaf5573 (2016).
135. East-Seletsky, A. et al. Two distinct RNase activities of CRISPR-C2c2 enable guide-RNA processing and RNA detection. Nature 538, 270-273 (2016).
136. Klein, A. M. et al. Droplet barcoding for single-cell transcriptomics applied to embryonic stem cells. Cell 161, 1187-1201 (2015).
137. Macosko, E. Z. et al. Highly parallel genome-wide expression profiling of individual cells using nanoliter droplets. Cell 161, 1202-1214 (2015).
138. Adamson, B. et al. A multiplexed single-cell CRISPR screening platform enables systematic dissection of the unfolded protein response. Cell 167, 1867-1882. e21 (2016).
139. Dixit, A. et al. Perturb-Seq: dissecting molecular circuits with scalable single-cell RNA profiling of pooled genetic screens. Cell 167, 1853-1866.e17 (2016).
140. Jaitin, D. A. et al. Dissecting immune circuits by linking CRISPR-pooled screens with single-cell RNASeq. Cell 167, 1883-1896.e15 (2016).
141. Marraffini, L. A. CRISPR-Cas immunity in prokaryotes. Nature 526, 55-61 (2015).
142. Pourcel, C., Salvignol, G. & Vergnaud, G. CRISPR elements in Yersinia pestis acquire new repeats by preferential uptake of bacteriophage DNA, and provide additional tools for evolutionary studies. Microbiology 151, 653-663 (2005).
143. Deltcheva, E. et al. CRISPR RNA maturation by transencoded small RNA and host factor RNase III. Nature 471, 602-607 (2011).
144. Garneau, J. E. et al. The CRISPR/Cas bacterial immune system cleaves bacteriophage and plasmid DNA. Nature 468, 67-71 (2010).
145. Marraffini, L. A. & Sontheimer, E. J. Self versus nonself discrimination during CRISPR RNA-directed immunity. Nature 463, 568-571 (2010).
146. Mojica, F. J., Diez-Villasenor, C., Garcia-Martinez, J. & Almendros, C. Short motif sequences determine the targets of the prokaryotic CRISPR defence system. Microbiology 155, 733-740 (2009).
147. Horvath, P. et al. Diversity, activity, and evolution of CRISPR loci in Streptococcus thermophilus. J. Bacteriol. 190, 1401-1412 (2008).
148. Jiang, F., Zhou, K., Ma, L., Gressel, S. & Doudna, J. A. A Cas9-guide RNA complex preorganized for target DNA recognition. Science 348, 1477-1481 (2015).
149. O'Connell, M. R. et al. Programmable RNA recognition and cleavage by CRISPR/Cas9. Nature 516, 263-266 (2014).
150. Jinek, M. et al. Structures of Cas9 endonucleases reveal RNA-mediated conformational activation. Science 343, 1247997 (2014).
151. Wiedenheft, B. et al. RNA-guided complex from a bacterial immune system enhances target recognition through seed sequence interactions. Proc. Natl Acad. Sci. USA 108, 10092-10097 (2011).
152. Haurwitz, R. E., Jinek, M., Wiedenheft, B., Zhou, K. & Doudna, J. A. Sequence-and structure-specific RNA processing by a CRISPR endonuclease. Science 329, 1355-1358 (2010).
153. Hale, C. R. et al. RNA-guided RNA cleavage by a CRISPR RNA-Cas protein complex. Cell 139, 945-956 (2009).
154. Gilbert, L. A. et al. CRISPR-mediated modular RNAguided regulation of transcription in eukaryotes. Cell 154, 442-451 (2013).
155. Gilbert, L. A. et al. Genome-scale CRISPR-mediated control of gene repression and activation. Cell 159, 647-661 (2014).
156. Dominguez, A. A., Lim, W. A. & Qi, L. S. Beyond editing: repurposing CRISPR-Cas9 for precision genome regulation and interrogation. Nat. Rev. Mol. Cell Biol. 17, 5-15 (2016).
157. Konermann, S. et al. Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex. Nature 517, 583-588 (2015).
158. Landry, D. M., Hertz, M. I. & Thompson, S. R. RPS25 is essential for translation initiation by the Dicistroviridae and hepatitis C viral IRESs. Genes Dev. 23, 2753-2764 (2009).
159. Scheel, T. K. & Rice, C. M. Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. Nat. Med. 19, 837-849 (2013).
160. Jopling, C. L., Yi, M., Lancaster, A. M., Lemon, S. M. & Sarnow, P. Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science 309, 1577-1581 (2005).
161. Shwetha, S. et al. HuR displaces polypyrimidine tract binding protein to facilitate La binding to the 3? untranslated region and enhances hepatitis C virus replication. J. Virol. 89, 11356-11371 (2015).
162. Chen, B. et al. Dynamic imaging of genomic loci in living human cells by an optimized CRISPR/Cas system. Cell 155, 1479-1491 (2013).
163. Baggen, J. et al. Enterovirus D68 receptor requirements unveiled by haploid genetics. Proc. Natl Acad. Sci. USA 113, 1399-1404 (2016).
164. Kleinfelter, L. M. et al. Haploid genetic screen reveals a profound and direct dependence on cholesterol for hantavirus membrane fusion. mBio 6, e00801 (2015).
165. Petersen, J. et al. The major cellular sterol regulatory pathway is required for Andes virus infection. PLoS Pathog. 10, e1003911 (2014).
166. Jae, L. T. et al. Deciphering the glycosylome of dystroglycanopathies using haploid screens for lassa virus entry. Science 340, 479-483 (2013).
167. Riblett, A. M. et al. A haploid genetic screen identifies heparan sulfate proteoglycans supporting Rift Valley Fever virus infection. J. Virol. 90, 1414-1423 (2016).